Emerging treatments for major depression.

about

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models Plasma and cerebrospinal fluid substance P in post-stroke patients with depression.

P2860

Q28305100-C528FFBB-E6B9-4453-A647-001C4CAF895E Q33557520-4404AC05-E792-4977-A4AE-2D81E9DA3AD1 Q48545385-97DEDB25-7AB8-4CF1-9FA1-6C320F83F1DC

P2860

Emerging treatments for major depression.

Item

http://www.wikidata.org/entity/Q36730674

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Emerging treatments for major depression.

@ast

Emerging treatments for major depression.

@en

type

Item

label

Emerging treatments for major depression.

@ast

Emerging treatments for major depression.

@en

prefLabel

Emerging treatments for major depression.

@ast

Emerging treatments for major depression.

@en

P1476

Emerging treatments for major depression.

@en

P2093

Graham D Burrows

http://www.w3.org/2001/XMLSchema#string

Trevor R Norman

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular characterization of the melanin-concentrating-hormone receptor

Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Rapid reversal of psychotic depression using mifepristone

The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways

Third-generation antidepressants: do they offer advantages over the SSRIs?

Novel naphthalenic ligands with high affinity for the melatonin receptor

Pramipexole in treatment-resistant depression: a 16-week naturalistic study

Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

P304

203-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737175.7.2.203

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17286553

http://www.w3.org/2001/XMLSchema#string

Emerging treatments for major depression.

about

P2860

P2860

Emerging treatments for major depression.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698